Monday, April 12, 2021 7:27:54 AM
Eric Feigl-Ding @DrEricDing - The most important vaccine in Latin America—SinoVac’s CoronaVac reports new trial results from Brazil Flag of Brazil—
Efficacy against symptomatic #COVID19–50.7%. Moderate & severe: 83.7% / 100%. Delayed 2nd dose no issue. Neut. titres lower in age>=60 against #P1.
Thread
https://papers.ssrn.com/sol3/papers.cfm?abstract_id=3822780
Efficacy against symptomatic #COVID19–50.7%. Moderate & severe: 83.7% / 100%. Delayed 2nd dose no issue. Neut. titres lower in age>=60 against #P1.
Thread
https://papers.ssrn.com/sol3/papers.cfm?abstract_id=3822780
The most important vaccine in Latin America—SinoVac’s CoronaVac reports new trial results from Brazil 🇧🇷—
— Eric Feigl-Ding (@DrEricDing) April 12, 2021
Efficacy against symptomatic #COVID19–50.7%. Moderate & severe: 83.7% / 100%. Delayed 2nd dose no issue. Neut. titres lower in age>=60 against #P1.🧵https://t.co/tMg6Kn8TAe pic.twitter.com/XtHo9gnAzO
Join the InvestorsHub Community
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
